In KEYNOTE 010, a phase-III open-label, randomized trial, patients with stage IIIB/IV NSCLC and PD-L1 TPS > 1% were randomized to receive either pembrolizumab monotherapy or docetaxel as the second-line treatment, following progression after at least two cycles of platinum-based chemotherapy [7]. Here, CD274 is linked to non-small cell lung carcinoma.